For the Inventor, By the Inventor

Enter assignee name

Lachen, Switzerland

Octapharma Ag

USPTO Granted Patents = 52

% Expired Patents = 25.0

CIPO Patents = 5

EPO Patents = 33

Trademarks = 16

Forward Citations = 183

Loading Chart...

Loading Chart...

81 inventors (with patents filed for the assignee):

Stefan Winge (14 out of 20 patents)

Werner Gehringer (7 out of 7 patents)

Petra Schulz (6 out of 6 patents)

4. Djuro Josic (6 out of 9 patents)

5. Monika Stadler (5 out of 5 patents)

6. Horst Schwinn (5 out of 16 patents)

7. Rainer Pape (4 out of 4 patents)

8. Karin Ahrer (4 out of 4 patents)

9. Waltraud Kaar (4 out of 4 patents)

10. Christoph Kannicht (4 out of 4 patents)

11. Gustav Gilljam (4 out of 4 patents)

12. Gerhard Gruber (4 out of 4 patents)

13. Jürgen Römisch (3 out of 3 patents)

14. Guido Kohla (3 out of 3 patents)

15. Barbara Solecka-Witulska (3 out of 3 patents)

Core Competencies:

Immunoglobulin Composition

Coagulation Factors

Factor VIII

Protein Purification

Recombinant Proteins

Pharmacokinetics

VWF Fusion Proteins

Stabilizing Agents

Virus Inactivation

Transfection Methods

Fibrinogen Production

Allele Modification

52 patents: Sort by Forward Citations

1. 12274738 - FX activation process and its use in the preparation of a FXa composition (2025-04-14),

2. 12233126 - High concentration immunoglobulin composition for pharmaceutical application (2025-02-25),

3. 12171808 - Glycosylated VWF fusion proteins with improved pharmacokinetics (2024-12-24),

4. 12083171 - C1-esterase inhibitor preparation (2024-09-10),

5. 11738069 - Polypeptides modulating SIGLEC dependent immune responses (2023-08-29),

6. 11713458 - Means and methods for modifying multiple alleles (2023-08-01),

7. 11401300 - Process for production of fibrinogen and fibrinogen produced thereby (2022-08-02),

8. 11383002 - Plasma-based films and methods for making and using the same (2022-07-12),

9. 11383001 - Plasma-based films and methods for making and using the same (2022-07-12),

10. 11191833 - High concentration immunoglobulin composition for pharmaceutical application (2021-12-07),

11. 11013789 - Polypeptides modulating SIGLEC dependent immune responses (2021-05-25),

12. 10889630 - Method of separating Factor VIII from blood products (2021-01-12),

13. 10822393 - Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG (2020-11-03),

14. 10640548 - Method for inactivation/removal of coagulation factors by precipitation (2020-05-05),

15. 10626431 - Method for improved isolation of recombinantly produced proteins (2020-04-21),

Company Overview

Octapharma AG, headquartered in Lachen, Switzerland, is a leading biopharmaceutical company specializing in the development and manufacture of human proteins. The organization focuses on immunoglobulin compositions and coagulation factors, particularly Factor VIII, to address various medical conditions. Their expertise extends to protein purification, recombinant proteins, and pharmacokinetics, with a commitment to advancing therapies that enhance patient care. Octapharma is dedicated to innovation in the field of biopharmaceuticals, contributing significantly to the treatment of bleeding disorders and immune deficiencies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

52 Patents

#1 in Lachen

#283 in Switzerland

#13,545 in the World

Lachen, Switzerland

Octapharma Ag

Forward Citations = 183

81 inventors:

Stefan Winge (14 out of 20 patents)

Werner Gehringer (7 out of 7 patents)

Petra Schulz (6 out of 6 patents)

4. Djuro Josic (6 out of 9 patents)

5. Monika Stadler (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Octapharma Ag. Retrieved from https://idiyas.com/company/octapharma-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…